Advertisement

Journal of Assisted Reproduction and Genetics

, Volume 35, Issue 8, pp 1371–1376 | Cite as

Case-based care for pre-existing or new-onset mood disorders in patients undergoing infertility therapy

  • Dikea Roussos-Ross
  • Alice S. Rhoton-Vlasak
  • Katherine M. Baker
  • Brittany J. Arkerson
  • Georgia Graham
Opinion
  • 74 Downloads

Abstract

The inability to conceive is an immensely stressful event in a woman’s life. Thus, it is no surprise that women with infertility have twice the rates of depressive symptoms as women without infertility. Incidence of depression in the general female population is approximately 20% compared to almost 40% in infertile females. Based on this information, we expect many individuals with infertility to have pre-existing mood disorders requiring ongoing treatment. In addition, we expect a subset of women to develop a mood disorder during infertility treatment due to related stressors. The reproductive endocrinology team must understand the impact of stress on pregnancy outcomes, the types of treatment options, and the safety and use of various medications. The goal of this case-based commentary is to summarize information on the relationship between stress and infertility and to offer a guide for a range of treatment options that include non-pharmacologic and pharmacologic therapies.

Keywords

Antidepressants Anxiety Depression Infertility Therapy 

Notes

Acknowledgments

The authors acknowledge Judy T. Walsh (Department of Obstetrics and Gynecology, University of Florida College of Medicine) for her editorial assistance.

References

  1. 1.
    Chen TH, Chang SP, Tsai CF, Juang KD. Prevalence of depressive and anxiety disorders in an assisted reproductive technique clinic. Hum Reprod. 2004;19(10):2313–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Domar AD, Broome A, Zuttermeister PC, Seibel M, Friedman R. The prevalence and predictability of depression in infertile women. Fertil Steril. 1992;58(6):1158–63.CrossRefPubMedGoogle Scholar
  3. 3.
    Volgsten H, Skoog Svanberg A, Ekselius L, Lundkvist O, Sundstrom Poromaa I. Prevalence of psychiatric disorders in infertile women and men undergoing in vitro fertilization treatment. Hum Reprod. 2008;23(9):2056–63.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Newton CR, Hearn MT, Yuzpe AA. Psychological assessment and follow-up after in vitro fertilization: assessing the impact of failure. Fertil Steril. 1990;54(5):879–86.CrossRefPubMedGoogle Scholar
  5. 5.
    Lok IH, Lee DT, Cheung LP, Chung WS, Lo WK, Haines CJ. Psychiatric morbidity amongst infertile Chinese women undergoing treatment with assisted reproductive technology and the impact of treatment failure. Gynecol Obstet Investig. 2002;53(4):195–9.CrossRefGoogle Scholar
  6. 6.
    Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8–19.CrossRefPubMedGoogle Scholar
  7. 7.
    Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol. 1997;12(1):19–29.CrossRefPubMedGoogle Scholar
  8. 8.
    Domar AD, Smith K, Conboy L, Iannone M, Alper M. A prospective investigation into the reasons why insured United States patients drop out of in vitro fertilization treatment. Fertil Steril. 2010;94(4):1457–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Campagne DM. Should fertilization treatment start with reducing stress? Hum Reprod. 2006;21(7):1651–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Whirledge S, Cidlowski JA. Glucocorticoids, stress, and fertility. Minerva Endocrinol. 2010;35(2):109–25.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Schenker JG, Meirow D, Schenker E. Stress and human reproduction. Eur J Obstet Gynecol Reprod Biol. 1992;45(1):1–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Sanders KA, Bruce NW. A prospective study of psychosocial stress and fertility in women. Hum Reprod. 1997;12(10):2324–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Ebbesen SM, Zachariae R, Mehlsen MY, Thomsen D, Hojgaard A, Ottosen L, et al. Stressful life events are associated with a poor in-vitro fertilization (IVF) outcome: a prospective study. Hum Reprod. 2009;24(9):2173–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Williams KE, Marsh WK, Rasgon NL. Mood disorders and fertility in women: a critical review of the literature and implications for future research. Hum Reprod Update. 2007;13(6):607–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Jonsson SA. Marriage rate and fertility in cycloid psychosis: comparison with affective disorder, schizophrenia and the general population. Eur Arch Psychiatry Clin Neurosci. 1991;241(2):119–25.CrossRefPubMedGoogle Scholar
  16. 16.
    Odegard O. Fertility of psychiatric first admissions in Norway 1936-1975. Acta Psychiatr Scand. 1980;62(3):212–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2003;60(1):29–36.CrossRefPubMedGoogle Scholar
  18. 18.
    Nillni YI, Wesselink AK, Gradus JL, Hatch EE, Rothman KJ, Mikkelsen EM, et al. Depression, anxiety, and psychotropic medication use and fecundability. Am J Obstet Gynecol. 2016;215(4):453.e1–8.CrossRefGoogle Scholar
  19. 19.
    Ramezanzadeh F, Noorbala AA, Abedinia N, Rahimi Forooshani A, Naghizadeh MM. Psychiatric intervention improved pregnancy rates in infertile couples. Malays J Med Sci. 2011;18(1):16–24.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Domar AD, Gross J, Rooney K, Boivin J. Exploratory randomized trial on the effect of a brief psychological intervention on emotions, quality of life, discontinuation, and pregnancy rates in in vitro fertilization patients. Fertil Steril. 2015;104(2):440–51. e7CrossRefPubMedGoogle Scholar
  21. 21.
    Pedro J, Sobral MP, Mesquita-Guimaraes J, Leal C, Costa ME, Martins MV. Couples’ discontinuation of fertility treatments: a longitudinal study on demographic, biomedical, and psychosocial risk factors. J Assist Reprod Genet. 2017;34(2):217–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Frederiksen Y, Farver-Vestergaard I, Skovgard NG, Ingerslev HJ, Zachariae R. Efficacy of psychosocial interventions for psychological and pregnancy outcomes in infertile women and men: a systematic review and meta-analysis. BMJ Open. 2015;5(1):e006592.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Facchinetti F, Tarabusi M, Volpe A. Cognitive-behavioral treatment decreases cardiovascular and neuroendocrine reaction to stress in women waiting for assisted reproduction. Psychoneuroendocrinology. 2004;29(2):162–73.CrossRefPubMedGoogle Scholar
  24. 24.
    Smith JF, Eisenberg ML, Millstein SG, Nachtigall RD, Shindel AW, Wing H, et al. The use of complementary and alternative fertility treatment in couples seeking fertility care: data from a prospective cohort in the United States. Fertil Steril. 2010;93(7):2169–74.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zheng CH, Huang GY, Zhang MM, Wang W. Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril. 2012;97(3):599–611.CrossRefPubMedGoogle Scholar
  26. 26.
    Domar AD, Rooney KL, Wiegand B, Orav EJ, Alper MM, Berger BM, et al. Impact of a group mind/body intervention on pregnancy rates in IVF patients. Fertil Steril. 2011;95(7):2269–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Oron G, Allnutt E, Lackman T, Sokal-Arnon T, Holzer H, Takefman J. A prospective study using Hatha Yoga for stress reduction among women waiting for IVF treatment. Reprod BioMed Online. 2015;30(5):542–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336(4):258–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159(11):1889–95.CrossRefPubMedGoogle Scholar
  30. 30.
    Alwan S, Bandoli G, Chambers CD. Maternal use of selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. Clin Pharmacol Ther. 2016;100(1):34–41.CrossRefPubMedGoogle Scholar
  31. 31.
    Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87.CrossRefPubMedGoogle Scholar
  32. 32.
    Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009;84(1):23–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79(4):301–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011;118(1):111–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ. 2005;173(11):1320–1.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry. 2008;165(6):749–52.CrossRefPubMedGoogle Scholar
  38. 38.
    Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;350:h1798.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397–407.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    ACOG. Practice Bulletin No. 92: use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001–20.CrossRefGoogle Scholar
  41. 41.
    Akioyamen LE, Minhas H, Holloway AC, Taylor VH, Akioyamen NO, Sherifali D. Effects of depression pharmacotherapy in fertility treatment on conception, birth, and neonatal health: a systematic review. J Psychosom Res. 2016;84:69–80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Dikea Roussos-Ross
    • 1
  • Alice S. Rhoton-Vlasak
    • 1
  • Katherine M. Baker
    • 1
  • Brittany J. Arkerson
    • 1
  • Georgia Graham
    • 1
  1. 1.Department of Obstetrics and GynecologyUniversity of Florida College of MedicineGainesvilleUSA

Personalised recommendations